Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab

Archives of Ophthalmology

Volumn 130, Issue 9, 2012, Pages 1153-1161

  Bressler, Susan B ^a   Qin, Haijing ^b   Beck, Roy W ^b   Chalam, Kakarla V ^c   Kim, Judy E ^d   Melia, Michele ^b   Wells III, John A ^e  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JAEB CENTER FOR HEALTH RESEARCH   (United States)

^c UNIVERSITY OF FLORIDA HEALTH SCIENCE CENTER   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e Palmetto Retina Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; TRIAMCINOLONE ACETONIDE;

ADULT; ARTICLE; CENTRAL SUBFIELD THICKNESS; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DRUG TREATMENT FAILURE; EYE PHOTOGRAPHY; FEMALE; FOLLOW UP; GROUPS BY AGE; HUMAN; LOW LEVEL LASER THERAPY; MAJOR CLINICAL STUDY; MALE; OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA EXUDATE; TREATMENT OUTCOME; VISION TEST; VISUAL ACUITY; VISUAL IMPAIRMENT; VISUAL SYSTEM PARAMETERS;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DIABETIC RETINOPATHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; LASER COAGULATION; MACULAR EDEMA; MALE; MIDDLE AGED; ORGAN SIZE; RETINA; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 84866092409     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2012.1107     Document Type: Article

References (15)

1. Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic population. Ophthalmology. 1998;105(6):998-1003. (Pubitemid 28268322)
2. Centers for Disease Control and Prevention (CDC). Overweight and obesity: data and statistics. Adult obesity. CDC website. http://www.cdc.gov/obesity/ data/adult.html. Accessed December 14, 2011.
3. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol. 1985;103(12):1796-1806.
4. Antonetti DA, Barber AJ, Hollinger LA, Wolpert EB, Gardner TW. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1: a potential mechanism for vascular permeability in diabetic retinopathy and tumors. J Biol Chem. 1999;274(33):23463-23467.
5. Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology. 2010;117 (6):1078.e2-1086.e2.
6. Do DV, Schmidt-Erfurth U, Gonzalez VH, et al. The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema. Ophthalmology. 2011;118(9):1819-1826.
7. Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117(6):1064.e35- 1077.e35.
8. Elman MJ, Bressler NM, Qin H, et al Diabetic Retinopathy Clinical Research Network. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2011;118(4):609-614.
9. Bressler NM, Edwards AR, Antoszyk AN, et al Diabetic Retinopathy Clinical Research Network. Retinal thickness on Stratus optical coherence tomography in people with diabetes and minimal or no diabetic retinopathy. Am J Ophthalmol. 2008;145(5):894-901.
10. Ferris FL III, Miller KM, Glassman AR, Beck RW; Diabetic Retinopathy Clinical Research Network. A proposed method of logarithmic transformation of optical coherence tomography data for use in clinical research. Ophthalmology. 2010; 117(8):1512-1516.
11. Zou G. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159(7):702-706. (Pubitemid 38405384)
12. Nguyen QD, Shah SM, Khwaja AA, et al; READ-2 Study Group. Two-year outcomes of the Ranibizumab for Edema of the Macula in Diabetes (READ-2) Study [published correction appears in Ophthalmology . 2011;118(6):1016]. Ophthalmology. 2010;117(11):2146-2151.
13. Mitchell P, Bandello F, Schmidt-Erfurth U, et al; RESTORE study group. The RESTORE Study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118(4):615-625.
14. Cunningham ET Jr, Adamis AP, Altaweel M, et al Macugen Diabetic Retinopathy Study Group. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology. 2005;112(10):1747-1757.
15. Boyer DS, Antoszyk AN, Awh CC, Bhisitkul RB, Shapiro H, Acharya NR; MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2007;114(2):246-252. (Pubitemid 46172497)